EN
抗体药类似物
Research Grade Diridavumab
All
TD-VK515016_1.jpg
TD-VK515016_2.jpg
  • CatalogTD-VK515016
  • ClonalitymAb
  • Application Research Grade Biosimilar
  • SynonymsCR-6261,CR6261,CAS:1393659-46-5
  • 规格
    1mg
  • 价格
    ¥询价
定制服务咨询

Research Grade Diridavumab


Catalog No. TD-VK515016
Description Diridavumab, the alternative name, CR6261, is a human monoclonal antibody directed against influenza A hemagglutinin. The CR6261 antibody was first discovered by the Scripps Institute and Crucell, a Dutch biopharmaceutical company, and later developed by Janssen Pharmaceutical Companies of Johnson & Johnson under the trade name diridavumab. Cr6261 is under investigation in clinical trial NCT02016066 (A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of Diridavumab in Japanese Healthy Participants).
Species reactivity Influenza A virus
Applications Research Grade Biosimilar
Host species Human
Isotype IgG1, lambda
Expression system Mammalian Cells
Clonality Monoclonal
Target HA/Hemagglutinin
Endotoxin level Please contact the lab for this information.
Purity >95% purity as determined by SDS-PAGE.
Purification Protein A/G, purified from cell culture supernatant.
Accession P03455
Form Liquid
Storage buffer 0.01M PBS,pH7.4.
Stability and Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternate Names CR-6261,CR6261,CAS:1393659-46-5
Background Diridavumab is a monoclonal anti-HA stalk antibody. Diridavumab stabilizes the prefusion HA structure and prevents pH-dependent fusion of cellular and viral membranes in endosomes. Diridavumab can be used in research of H2 influenza virus.
Note For research use only. Not for use in clinical or therapeutic applications.

 

TD-VK515016_1.jpg
Bioactivity
 
SEC-HPLC detection for Research Grade Diridavumab.
TD-VK515016_2.jpg
SDS-PAGE
 
SDS-PAGE for Research Grade Diridavumab.